When CMS bans a Medicare-enrolled medical supply company, it revokes that supplier's billing privileges, meaning Medicare will no longer pay any claims the company submits — and beneficiaries who continue using that supplier risk being left with unexpected out-of-pocket bills.

What DMEPOS Suppliers Are and Why They Require Medicare Enrollment

DMEPOS stands for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies. This category covers a wide range of products that Medicare Part B pays for, including wheelchairs, oxygen equipment, CPAP machines, diabetic testing supplies, and hospital beds used at home. Any company that wants to bill Medicare for these items must first obtain enrollment approval through the National Supplier Clearinghouse, a CMS contractor that vets suppliers against 30 specific standards outlined in 42 CFR § 424.57.

Those standards require suppliers to maintain a physical facility that is open during posted business hours, employ qualified staff, keep accurate delivery and patient records, and comply with all applicable state licensing laws. Suppliers must also carry liability insurance and cannot have owners or managing employees with prior felony convictions related to health care fraud. These requirements exist because DMEPOS has historically been one of the highest-fraud categories in the entire Medicare program.

How CMS Revokes Enrollment and Imposes Bans

CMS has authority under 42 CFR § 424.535 to revoke a supplier's Medicare billing privileges for a range of violations. Common grounds include submitting claims for equipment never delivered, billing for higher-cost items than were actually provided, operating without a valid state license, and failing a site visit conducted by a CMS contractor. Revocation can also occur when a supplier's owner or operator is excluded from federal health care programs by the OIG.

Once revoked, a supplier faces a re-enrollment bar that CMS can set anywhere from one to ten years depending on the severity of the conduct. In cases involving felony convictions or large-scale fraud schemes, CMS may also refer the matter to the Department of Justice. Between 2020 and 2023, CMS revoked billing privileges from more than 76,000 providers and suppliers across all categories, with DMEPOS consistently representing a disproportionate share of those actions.

The agency also uses a tool called the Automated Provider Enrollment system to flag suppliers that show patterns consistent with fraud before a formal investigation is complete. Suppliers identified through this system can have their payments suspended under 42 CFR § 405.371 while a review is ongoing, which effectively halts their operations even without a final revocation order.

The Role of Competitive Bidding in Reducing Fraud

CMS introduced the DMEPOS Competitive Bidding Program to address both cost and fraud simultaneously. Under this program, suppliers in designated geographic areas must submit bids to win contracts for specific product categories. Only winning bidders can supply Medicare beneficiaries in those areas at the contracted price. The program has been credited with reducing Medicare spending on certain equipment categories by more than 40 percent since its first round in 2011, while also shrinking the pool of eligible suppliers to those who can demonstrate financial stability and compliance.

Beneficiaries in competitive bidding areas must use contract suppliers for covered items or pay the full cost themselves. This requirement gives CMS additional leverage because a supplier that loses its contract through a fraud finding is immediately cut off from a large patient base.

What Happens to Beneficiaries When a Supplier Is Banned

The practical consequences for patients can be significant. If a supplier is revoked mid-rental — oxygen equipment, for example, is often rented on a monthly basis — the beneficiary may face a gap in service while locating a new enrolled supplier. Medicare does not automatically transfer ongoing rental agreements to a new company. The beneficiary or their caregiver must initiate that process.

For one-time purchases like a power wheelchair, a revocation after delivery but before the claim is paid can result in Medicare denying the claim entirely if the supplier's billing privileges were already suspended at the time of service. In those situations, beneficiaries have appeal rights under Medicare's standard claims appeal process, which begins with a redetermination request submitted to the Medicare Administrative Contractor within 120 days of the denial notice.

CMS publishes a list of excluded individuals and entities through the OIG, and the Medicare Supplier Directory at Medicare.gov allows beneficiaries to search for currently enrolled suppliers by product type and zip code. Using these tools before accepting any equipment is the most reliable way to avoid coverage gaps.

Recognizing the Warning Signs of a Fraudulent Supplier

Fraudulent DMEPOS suppliers often contact beneficiaries unsolicited by phone or door-to-door, offering free equipment in exchange for a Medicare number. They may claim a doctor has already approved the item or pressure beneficiaries to accept products they did not request. Legitimate suppliers do not cold-call Medicare beneficiaries, and Medicare itself prohibits suppliers from doing so under its marketing rules.

Other red flags include suppliers who cannot provide a physical address, who ask beneficiaries to sign blank delivery forms, or who offer cash payments in exchange for Medicare information. These tactics are associated with schemes that have cost Medicare billions of dollars annually and have resulted in federal prosecutions across multiple states.

What CMS and Congress Are Doing Next

CMS finalized updates to its supplier enrollment rules in 2023 that expanded the agency's authority to deny enrollment to suppliers with a pattern of compliance problems, even if no single violation would independently trigger revocation. The agency also increased the frequency of revalidation reviews, now requiring DMEPOS suppliers to revalidate their enrollment every three years rather than every five.

Legislation introduced in the 118th Congress, including provisions in broader Medicare fraud reduction bills, proposed giving CMS authority to require surety bonds of up to $65,000 for high-risk supplier categories and to conduct unannounced site visits at any time. Whether those provisions advance in the 119th Congress remains to be seen, but the regulatory direction is clearly toward tighter gatekeeping at the enrollment stage rather than relying solely on post-payment audits.